Roche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias

Features Dow Jones Newswires

Within a few weeks of each other, the U.S. Food and Drug Administration and the European Medicines Agency have approved the authorization of the sale of Herceptin biosimilars, Spain's Cinco Dias reports.

Continue Reading Below

--Herceptin is a drug developed by Roche Holding AG (ROG.EB) for the treatment breast cancer.

--Cinco Dias says that on Dec. 1, the FDA approved the biosimilar Ogivri, developed by Mylan NV (MYL). The news comes only a few days after the European Medicines Agency authorized the commercialization of Ontruzant on Nov. 20, developed by Samsung Bioepis, a joint venture created by Samsung Electronics Co. Ltd. (005930.SE) and Biogen Inc. (IIB).

--In general, the price for biosimilars is around 20% to 25% lower than patented drugs, Cinco Dias reports, which could force the Swiss company to lower its prices to fight competition in some countries.

--Herceptin generated 5.9 billion euros ($6.99 billion) in sales last year for Roche, it says.

Full story: http://bit.ly/2AS5WWj

Continue Reading Below

Write to Barcelona editors at barcelonaeditors@dowjones.com

(END) Dow Jones Newswires

December 05, 2017 06:07 ET (11:07 GMT)